TAC1 (Tachykinin Precursor 1) Protein

Migration, Crosslink

📖

TAC1 (Tachykinin Precursor 1) Protein

active

wiki page Created: 2026-04-02T07:19:14 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-tac1-protein

📖 Wiki Page

protein1709 wordssynced 2026-04-02

TAC1 Protein (Tachykinin Precursor 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TAC1 (Tachykinin Precursor 1) Protein</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Ligand</td>
</tr>
<tr>
<td class="label">NK1R (TACR1)</td>
<td>Substance P</td>
</tr>
<tr>
<td class="label">NK2R (TACR2)</td>
<td>Neurokinin A</td>
</tr>
<tr>
<td class="label">NK3R (TACR3)</td>
<td>Neurokinin B</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Aprepitant</td>
<td>AD</td>
</tr>
<tr>
<td class="label">NK1 antagonist</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Substance P analog</td>
<td>MS</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>

Overview

...

TAC1 Protein (Tachykinin Precursor 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TAC1 (Tachykinin Precursor 1) Protein</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Ligand</td>
</tr>
<tr>
<td class="label">NK1R (TACR1)</td>
<td>Substance P</td>
</tr>
<tr>
<td class="label">NK2R (TACR2)</td>
<td>Neurokinin A</td>
</tr>
<tr>
<td class="label">NK3R (TACR3)</td>
<td>Neurokinin B</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Aprepitant</td>
<td>AD</td>
</tr>
<tr>
<td class="label">NK1 antagonist</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Substance P analog</td>
<td>MS</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>

Overview

TAC1 (Tachykinin Precursor 1) is a gene encoding preprotachykinin, the precursor protein for the tachykinin peptide family, including [Substance P](/entities/substance-p) (SP), [Neurokinin A](/entities/neurokinin-a) (NKA), neuropeptide K (NPK), and neuropeptide γ (NPγ)[@severini2002]. These peptides function as neurotransmitters and neuromodulators throughout the central and peripheral nervous systems, playing critical roles in pain transmission, neuroinflammation, and stress responses. The TAC1 gene and its encoded peptides have emerged as significant players in the pathophysiology of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[@steinhoff2014].

The tachykinin system represents one of the oldest neuropeptide signaling systems in evolution, with conserved functions across species from amphibians to humans. In the mammalian brain, Substance P and Neurokinin A are expressed in distinct neuronal populations within the basal ganglia, cortex, hippocampus, and brainstem, where they modulate dopaminergic signaling, GABAergic transmission, and inflammatory responses[@chen2005].

Gene Structure and Alternative Splicing

The TAC1 gene is located on human chromosome 7q21-22 and spans approximately 9.5 kb. It consists of seven exons that undergo complex alternative splicing to generate multiple mRNA isoforms encoding distinct preprotachykinin variants[@euler2014]. The primary isoforms include:

Preprotachykinin-A (PPT-A): Generates Substance P (SP, 11 amino acids), Neurokinin A (NKA, 10 amino acids), neuropeptide K (NPK, 36 amino acids), and neuropeptide γ (NPγ, 21 amino acids)
Preprotachykinin-B (PPT-B): Generates Neurokinin B (NKB, 10 amino acids), encoded by the separate TAC3 gene

The expression of TAC1 is regulated by multiple transcription factors including AP-1, CREB, and NF-κB, allowing dynamic modulation in response to neuronal activity, stress, and inflammatory stimuli. Alternative promoter usage and exon skipping result in tissue-specific patterns of tachykinin peptide expression[@euler2014].

Protein Structure and Processing

Precursor Processing

The preprotachykinin precursor (approximately 15-17 kDa depending on isoform) undergoes post-translational processing in the secretory pathway to generate mature tachykinin peptides[@severini2002]:

Signal peptide cleavage: The N-terminal signal sequence is removed in the endoplasmic reticulum

Propeptide cleavage: Furin-like convertases cleave at dibasic residues (Lys-Arg, Arg-Arg) to release mature peptides

C-terminal amidation: The C-terminal glycine is amidated to produce the active peptide

Secretory granule packaging: Mature peptides are packaged into dense-core secretory vesicles

Tachykinin Peptide Receptors

The biological effects of TAC1-derived peptides are mediated through three G protein-coupled receptors[@steinhoff2014]:

NK1R has the highest affinity for Substance P and is the primary receptor mediating central nervous system effects of tachykinins. Receptor activation triggers phospholipase C activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to intracellular calcium mobilization and protein kinase C activation[@steinhoff2014].

Normal Physiological Functions

Pain and Nociception

Substance P serves as a primary neurotransmitter in nociceptive (pain-sensing) primary afferent neurons. In the dorsal horn of the spinal cord, Substance P is released from central terminals of C-fibers to transmit pain signals to second-order neurons[@kramer1998]. NK1R activation on spinal neurons contributes to:

Nociceptive transmission and central sensitization
Neurogenic inflammation and plasma extravasation
Modulation of opioid peptide release
Induction of mast cell degranulation

The tachykinin system is thus a critical component of the pain processing axis and has been targeted for analgesic drug development.

Neurotransmission and Modulation

In the brain, TAC1-derived peptides function as neuromodulators rather than classical neurotransmitters[@saria1999]:

Basal ganglia: Substance P is expressed in striatal medium spiny neurons and modulates dopaminergic signaling. The striatonigral and striatopallidal pathways contain Substance P that influences motor control.
Hippocampus: NK1R activation modulates hippocampal synaptic plasticity, memory formation, and seizure threshold.
Amygdala and hypothalamus: Tachykinins participate in stress responses, anxiety, and emotional processing.
Raphe nuclei: Substance P-containing neurons project to spinal cord pain transmission sites.

Immune Modulation

Substance P exerts potent pro-inflammatory effects through NK1R on immune cells[@khan2018]:

Microglia: Activation of microglial NK1R triggers release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and chemokines
Astrocytes: Tachykinin signaling promotes astrocyte reactivity and neuroinflammation
Peripheral immune cells: Substance P enhances neutrophil migration, macrophage phagocytosis, and T-cell activation

Role in Neurodegenerative Diseases

Alzheimer's Disease

Substance P and NK1R are altered in Alzheimer's disease brains, with implications for both amyloid pathology and neuroinflammation[@pichon2014][@hall2016][@riemer2016]:

Amyloid-Tachykinin Interactions:

Substance P can bind to amyloid-β (Aβ) peptides and influence their aggregation kinetics
NK1R activation promotes amyloid precursor protein (APP) processing toward amyloidogenic Aβ production
Aβ exposure upregulates TAC1 expression in neurons and glia, creating a feed-forward inflammatory loop

Neuroinflammation:

Elevated Substance P levels in AD brain correlate with neurofibrillary tangle burden[@riemer2016]
NK1R-mediated microglial activation contributes to chronic neuroinflammation
Substance P enhances tau phosphorylation through NK1R-GSK3β signaling

Therapeutic Implications:

NK1R antagonists reduce Aβ-induced neurotoxicity in cellular models
Preclinical studies show improved cognitive performance with NK1R blockade
Substance P imaging ligands detect neuroinflammation in living AD patients[@martinez2024]

Parkinson's Disease

The tachykinin system is intimately connected with dopaminergic neuron degeneration in Parkinson's disease[@behbehani1995][@toth2010]:

Basal Ganglia Dysfunction:

Substance P is highly expressed in substantia nigra pars compacta (SNc) dopaminergic neurons
NK1R is present on dopaminergic neurons and modulates dopamine release
Loss of Substance P-containing neurons contributes to motor dysfunction

Neuroinflammation:

Elevated CSF levels of Substance P reported in PD patients[@toth2010]
NK1R activation on microglia promotes dopaminergic neuron death
Tachykinin-mediated inflammation exacerbates α-synuclein pathology

Therapeutic Strategies:

NK1R antagonists protect dopaminergic neurons in experimental PD models[@liu2019][@zhang2023]
NK1R modulation reduces microglial activation and improves motor function
TAC1 gene expression analysis reveals dysregulation in PD substantia nigra[@walker2024]

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS):

Elevated Substance P in spinal cord and CSF of ALS patients
NK1R contributes to motor neuron excitotoxicity
NK1R antagonists show protective effects in SOD1 mouse models

Multiple Sclerosis (MS):

Substance P promotes demyelination and immune cell infiltration
NK1R blockade reduces disease severity in experimental autoimmune encephalomyelitis
Tachykinin system correlates with disease progression

Huntington's Disease:

TAC1 expression altered in striatal neurons
NK1R antagonists ameliorate behavioral deficits in HD models
Substance P modulates GABAergic signaling in the striatum

Molecular Mechanisms in Neurodegeneration

Signaling Pathways

NK1R activation triggers multiple intracellular signaling cascades relevant to neurodegeneration[@khan2018][@nielsen2020]:

Mermaid diagram (expand to render)

Neuroinflammation

Substance P promotes neuroinflammation through multiple mechanisms[@khan2018][@nielsen2020]:

Microglial activation: NK1R on microglia triggers NADPH oxidase activation and ROS production

Cytokine release: IL-1β, TNF-α, and IL-6 release from activated glia

Blood-brain barrier: NK1R activation increases BBB permeability

T-cell infiltration: Enhanced immune cell trafficking into CNS

Excitotoxicity

Tachykinin signaling can contribute to excitotoxic neuronal death:

NK1R activation increases glutamate release from presynaptic terminals
Enhanced NMDA receptor phosphorylation and function
Calcium dysregulation and mitochondrial dysfunction

Therapeutic Targeting

NK1 Receptor Antagonists

The tachykinin system has been targeted for drug development with NK1R antagonists[@kramer1998][@hall2016]:

Clinical Development:

Aprepitant (Emend®): FDA-approved antiemetic, crosses BBB
Fosaprepitant: Prodrug of aprepitant
L-759274: Advanced NK1 antagonist for CNS disorders

Neurodegeneration Applications:

Reduced neuroinflammation in AD/PD models
Decreased microglial activation
Improved cognitive and motor function in preclinical studies

Clinical Trials

Challenges and Future Directions

Blood-brain barrier penetration of NK1 antagonists
Receptor subtype selectivity (NK1 vs. NK2/NK3)
Timing of intervention in disease progression
Combination therapies targeting multiple neuroinflammatory pathways

Biomarker Potential

Tachykinin peptides show promise as biomarkers for neurodegenerative disease[@chen2022][@martinez2024]:

CSF Substance P: Elevated in PD, AD, and ALS
CSF Neurokinin A: Correlates with disease severity
Imaging ligands: NK1R PET tracers in development

Research Methods

Detection Techniques

Immunohistochemistry: NK1R and Substance P localization in brain tissue
ELISA: Quantitation of peptide levels in CSF and plasma
RT-PCR: TAC1 mRNA expression analysis
PET imaging: NK1R binding in living brain (emerging)
Single-cell RNA-seq: Cellular expression patterns[@walker2024]

Model Systems

In vitro: Primary neuron and glial cultures, iPSC-derived neurons
In vivo: Mouse models with genetic deletion of TAC1 or TACR1
Transgenic: APP/PS1 and α-synuclein transgenic mice

Cross-Links

[TAC1 Gene](/genes/tac1)
[Substance P](/entities/substance-p)
[Neurokinin A](/entities/neurokinin-a)
[NK1 Receptor](/entities/nk1-receptor)
[Tachykinin Signaling Pathway](/mechanisms/tachykinin-signaling)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Microglial Activation](/mechanisms/microglial-activation)

References

[Behbehani, The role of substance P in the pathophysiology of Parkinson's disease (1995)](https://pubmed.ncbi.nlm.nih.gov/7566391/)

[Euler et al., Alternative splicing of the TAC1 gene (2014)](https://pubmed.ncbi.nlm.nih.gov/24837663/)

[Kramer et al., A placebo-controlled trial of L-759274 (1998)](https://pubmed.ncbi.nlm.nih.gov/9821538/)

[Saria, The tachykinin NK1 receptor in the brain (1999)](https://pubmed.ncbi.nlm.nih.gov/10552389/)

[Mantyh et al., Substance P receptor binding sites in the brain (2002)](https://pubmed.ncbi.nlm.nih.gov/11854539/)

[Töth et al., Substance P in CSF of PD patients (2010)](https://pubmed.ncbi.nlm.nih.gov/20674582/)

[Chen et al., Tachykinin-containing neurons in the basal forebrain (2005)](https://pubmed.ncbi.nlm.nih.gov/15690379/)

[Severini et al., The tachykinin peptide family (2002)](https://pubmed.ncbi.nlm.nih.gov/12417552/)

[Steinhoff et al., Tachykinins and their receptors (2014)](https://pubmed.ncbi.nlm.nih.gov/25444413/)

[Pichon et al., Substance P and neuroinflammation in AD (2014)](https://pubmed.ncbi.nlm.nih.gov/24718957/)

[Hall et al., Tachykinin receptor antagonists for AD (2016)](https://pubmed.ncbi.nlm.nih.gov/27079729/)

[Riemer et al., Substance P levels correlate with tau pathology (2016)](https://pubmed.ncbi.nlm.nih.gov/27524684/)

[Khan et al., Tachykinin signaling in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29859518/)

[Liu et al., NK1 receptor and alpha-synuclein aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/30869125/)

[Nielsen et al., Substance P modulates microglial phagocytosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32442755/)

[Warner et al., Tachykinin dysfunction in PD striatum (2021)](https://pubmed.ncbi.nlm.nih.gov/34015127/)

[Chen et al., TAC1-derived peptides as biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35959274/)

[Zhang et al., Neuroprotective effects of NK1 modulation (2023)](https://pubmed.ncbi.nlm.nih.gov/36849012/)

[Walker et al., Single-cell analysis of tachykinin expression (2024)](https://pubmed.ncbi.nlm.nih.gov/38340256/)

[Martinez et al., Substance P receptor imaging in patients (2024)](https://pubmed.ncbi.nlm.nih.gov/38472391/)

📖 View canonical wiki page →

Related Entities

TAC1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-tac1-protein
kg_node_id	TAC1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1989f62f8376
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-tac1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TAC1 (Tachykinin Precursor 1) Protein

TAC1 Protein (Tachykinin Precursor 1)

Overview

TAC1 Protein (Tachykinin Precursor 1)

Overview

Gene Structure and Alternative Splicing

Protein Structure and Processing

Precursor Processing

Tachykinin Peptide Receptors

Normal Physiological Functions

Pain and Nociception

Neurotransmission and Modulation

Immune Modulation

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Molecular Mechanisms in Neurodegeneration

Signaling Pathways

Neuroinflammation

Excitotoxicity

Therapeutic Targeting

NK1 Receptor Antagonists

Clinical Trials

Challenges and Future Directions

Biomarker Potential

Research Methods

Detection Techniques

Model Systems

Cross-Links

References

💬 Discussion